Potential for improvement of docetaxel-based chemotherapy: a pharmacological review

被引：89

作者：

Engels, FK

Sparreboom, A

Mathot, RAA

Verweij, J

机构：

[1] Erasmus MC Daniel Den Hoed Canc Ctr Rotterdam, Dept Med Oncol, NL-3075 EA Rotterdam, Netherlands

[2] NCI, Clin Pharmacol Res Core, Med Oncol Clin Res Unit, Bethesda, MD 20892 USA

[3] Erasmus MC, Dept Hosp Pharm & Clin Pharmacol, Rotterdam, Netherlands

来源：

BRITISH JOURNAL OF CANCER | 2005年 / 93卷 / 02期

关键词：

docetaxel; taxotere; taxanes; pharmacology;

D O I：

10.1038/sj.bjc.6602698

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Since the introduction of docetaxel, research has focused on various approaches to overcome treatment limitations and improve outcome. This review discusses the pharmacological attempts at treatment optimisation, which include reducing interindividual pharmacokinetic and pharmacodynamic variability, optimising schedule, route of administration, reversing drug resistance and the development of structurally related second-generation taxanes. (c) 2005 Cancer Research UK.

引用

收藏

页码：173 / 177

页数：5

相关论文

共 30 条

[1] Relationship of systemic exposure to unbound docetaxel and neutropenia [J].

Baker, SD ;

Li, J ;

ten Tije, AJ ;

Figg, WD ;

Graveland, W ;

Verweij, J ;

Sparreboom, A .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (01) :43-53

[2]

Bardelmeijer HA, 2002, CANCER RES, V62, P6158

[3] Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme. [J].

Bournique, B ;

Lemarié, A .

DRUG METABOLISM AND DISPOSITION, 2002, 30 (11) :1149-1152

[4] Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer [J].

Bruno, R ;

Hille, D ;

Riva, A ;

Vivier, N ;

Huinnink, WWTB ;

van Oosterom, AT ;

Kaye, SB ;

Verweij, J ;

Fossella, FV ;

Valero, V ;

Rigas, JR ;

Seidman, AD ;

Chevallier, B ;

Fumoleau, P ;

Burris, HA ;

Ravclin, PM ;

Sheiner, LB .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :187-196

[5] A population pharmacokinetic model for docetaxel (Taxotere(R)): Model building and validation [J].

Bruno, R ;

Vivier, N ;

Vergniol, JC ;

DePhillips, SL ;

Montay, G ;

Sheiner, LB .

JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1996, 24 (02) :153-172

[6] Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization [J].

Chiou, WL ;

Jeong, HY ;

Wu, TC ;

Ma, C .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (04) :305-310

[7] Docetaxel administration schedule: From fever to tears? A review of randomised studies [J].

Engels, FK ;

Verweij, J .

EUROPEAN JOURNAL OF CANCER, 2005, 41 (08) :1117-1126

[8] Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel [J].

Engels, FK ;

ten Tije, AJ ;

Baker, SD ;

Lee, CKK ;

Loos, WJ ;

Vulto, AG ;

Verweij, J ;

Sparreboom, A .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (05) :448-454

[9] Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies [J].

Fracasso, PM ;

Goldstein, LJ ;

de Alwis, DP ;

Rader, JS ;

Arquette, MA ;

Goodner, SA ;

Wright, LP ;

Fears, CL ;

Gazak, RJ ;

Andre, VAM ;

Burgess, MF ;

Slapak, CA ;

Schellens, JHM .

CLINICAL CANCER RESEARCH, 2004, 10 (21) :7220-7228

[10] Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies [J].

Goh, BC ;

Lee, SC ;

Wang, LZ ;

Fan, L ;

Guo, JY ;

Lamba, J ;

Schuetz, E ;

Lim, R ;

Lim, HL ;

Ong, AB ;

Lee, HS .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3683-3690